Watchlist Price Alert

Stoke Therapeutics Inc. (STOK)

NASDAQ: STOK · Real-Time Price · USD

11.70

0.17 (1.47%)

At close: Jun 16, 2025, 3:59 PM

11.57

-1.11%

After-hours: Jun 16, 2025, 07:58 PM EDT

1.47% (1D)

Bid	9.1
Market Cap	638.78M
Revenue (ttm)	190.91M
Net Income (ttm)	50.27M
EPS (ttm)	0.82
PE Ratio (ttm)	14.27
Forward PE	-4.26
Analyst	Buy

Ask	12
Volume	340,719
Avg. Volume (20D)	818,006
Open	11.56
Previous Close	11.53
Day's Range	11.43 - 11.72
52-Week Range	5.35 - 16.62
Beta	1.10

About STOK

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol STOK

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for STOK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

6 months ago

+12.07%

Stoke Therapeutics shares are trading higher after... Unlock content with Pro Subscription

7 months ago

+1.53%

Stoke Therapeutics shares are trading higher on possible continued strength following Q3 reported financial results yesterday. Also, Needham and HC Wainwright & Co. reiterated Buy ratings on the stock.

News

1 day ago · seekingalpha.com

Stoke Therapeutics: Impressive Pipeline And Big Backers

Stoke Therapeutics is pioneering RNA-based therapies, with a lead candidate for Dravet Syndrome aiming for true disease modification, unlike current symptom-focused treatments. The company's pipeline ...

2 weeks ago · businesswire.com

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...

1 month ago · zacks.com

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

1 month ago · zacks.com

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.57 per share a year ...

1 month ago · businesswire.com

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

1 month ago · zacks.com

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?

Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · zacks.com

Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?

Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d...